Surgical Unit Department of Emergency and Organ Transplantation, University Aldo Moro of Bari, Bari,, Italy.
Surgical Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
Colorectal Dis. 2021 Jul;23(7):1814-1823. doi: 10.1111/codi.15685. Epub 2021 May 10.
The study aimed to show if transanal reinforcement of the suture line can prevent anastomotic leakage (AL) after rectal cancer surgery, thus avoiding the need for a covering ileostomy.
This is a prospective, multicentre, parallel-arm randomized controlled equivalence trial. After standard total mesorectal excision, patients with anastomotic line at 1-3 cm from the dentate line were randomized to have transanal suture reinforcement (TAR group) or protective ileostomy (PI group).
Twenty-nine patients had PI, 25 had TAR. The two groups were comparable both for baseline characteristics and intra-operative aspects. Clinically evident AL occurred in four (16%) and five (17.24%) patients of the TAR and PI group, respectively, resulting in a difference of -1.20% (90% CI -17.93, 15.45), while subclinical AL at proctography was absent in 15 (65.22%) and 13 (50%) patients of the TAR and PI groups, respectively, resulting in a difference of 15% (90% CI -7.74 to 38.17).
Preliminary data suggest that transanal reinforcement of the suture line performed in rectal cancer patients with suture line at 1-3 cm from the dentate line carries a similar (even if not equivalent) AL rate to covering ileostomy, suggesting that a covering ileostomy could be avoided in this selected group of patients. This indication needs to be addressed with future larger trials (clinicaltrials.gov ID number NCT02279771).
本研究旨在探讨经肛门直肠吻合口缝线加固是否能预防直肠癌术后吻合口漏(AL),从而避免行预防性回肠造口术。
这是一项前瞻性、多中心、平行臂随机对照等效试验。在标准全直肠系膜切除术后,将吻合口位于齿状线 1-3cm 处的患者随机分为经肛门缝线加固(TAR 组)或保护性回肠造口(PI 组)。
29 例患者行 PI,25 例行 TAR。两组在基线特征和术中方面具有可比性。TAR 和 PI 组分别有 4 例(16%)和 5 例(17.24%)患者发生临床明显的 AL,差异为-1.20%(90%CI-17.93,15.45),而直肠造影未见亚临床 AL 的患者分别为 15 例(65.22%)和 13 例(50%),差异为 15%(90%CI-7.74,38.17)。
初步数据表明,对于吻合口位于齿状线 1-3cm 处的直肠癌患者,经肛门直肠吻合口缝线加固与保护性回肠造口术具有相似(即使不等效)的 AL 发生率,提示在这组选定的患者中可以避免行保护性回肠造口术。这一适应证需要进一步通过更大规模的试验来证实(临床试验注册号:NCT02279771)。